Exponent (NASDAQ:EXPO – Get Free Report) posted its quarterly earnings results on Thursday. The business services provider reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.02, reports. The firm had revenue of $125.09 million for the quarter, compared to analyst estimates of $125.96 million. Exponent had a net margin of 19.35% and a return on equity of 28.39%.
Exponent Trading Down 8.9 %
NASDAQ EXPO traded down $9.44 during trading on Friday, reaching $96.92. 370,086 shares of the company’s stock were exchanged, compared to its average volume of 247,055. Exponent has a fifty-two week low of $64.61 and a fifty-two week high of $115.75. The company’s fifty day simple moving average is $108.99 and its 200-day simple moving average is $100.03. The firm has a market capitalization of $4.91 billion, a PE ratio of 48.95 and a beta of 0.66.
Exponent Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 20th. Investors of record on Friday, December 6th will be given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 1.16%. The ex-dividend date is Friday, December 6th. Exponent’s payout ratio is 56.57%.
Insider Transactions at Exponent
Institutional Trading of Exponent
A number of institutional investors have recently bought and sold shares of the company. Comerica Bank boosted its holdings in shares of Exponent by 8.7% during the 1st quarter. Comerica Bank now owns 231,131 shares of the business services provider’s stock worth $19,112,000 after buying an additional 18,429 shares during the period. Silvercrest Asset Management Group LLC grew its position in shares of Exponent by 6.8% in the first quarter. Silvercrest Asset Management Group LLC now owns 276,500 shares of the business services provider’s stock valued at $22,864,000 after purchasing an additional 17,496 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Exponent by 601.1% in the first quarter. SG Americas Securities LLC now owns 12,866 shares of the business services provider’s stock worth $1,064,000 after purchasing an additional 11,031 shares during the period. Raymond James & Associates lifted its position in shares of Exponent by 4.1% during the 2nd quarter. Raymond James & Associates now owns 487,035 shares of the business services provider’s stock worth $46,327,000 after purchasing an additional 19,051 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Exponent by 5.8% during the 1st quarter. Vanguard Group Inc. now owns 5,286,652 shares of the business services provider’s stock valued at $437,153,000 after purchasing an additional 291,047 shares during the period. Institutional investors and hedge funds own 92.37% of the company’s stock.
Analysts Set New Price Targets
Separately, Truist Financial reaffirmed a “buy” rating and set a $120.00 target price (up from $100.00) on shares of Exponent in a report on Friday, July 26th.
Read Our Latest Research Report on EXPO
About Exponent
Exponent, Inc, together with its subsidiaries, operates as a science and engineering consulting company in the United States and internationally. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health. The Engineering and Other Scientific segment provides services in the areas of biomechanics, biomedical engineering and sciences, buildings and structures, civil engineering, construction consulting, data sciences, electrical engineering and computer science, human factors, materials and corrosion engineering, mechanical engineering, polymer science and materials chemistry, thermal sciences, and vehicle engineering.
Recommended Stories
- Five stocks we like better than Exponent
- The Significance of Brokerage Rankings in Stock Selection
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Ride Out The Recession With These Dividend Kings
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Top Biotech Stocks: Exploring Innovation Opportunities
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Exponent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exponent and related companies with MarketBeat.com's FREE daily email newsletter.